PT-141 (Bremelanotide)
Also known as: Bremelanotide, Vyleesi, PT141
Centrally acting melanocortin agonist (bremelanotide) that drives sexual desire through brain dopamine and oxytocin pathways rather than blood flow. FDA-approved for low desire. Dosed SubQ or intranasally.
Pharmacokinetics
- Half-life
- 2.7 hours
- Time to peak
- 45 min
- Bioavailability
- 100%
- Onset
- 45 min
- Dosing interval
- 24h
Administration
- Primary routes
- SubQ, Intranasal
- Category
- Sexual Function & Libido
Safety Flags
No registry-level safety flags. Always check drug-peptide interactions for your specific stack in the Lab.
Storage
- · Requires refrigeration (2–8°C)
- · Temperature sensitive — minimise room-temp exposure
Used in 2 outcome protocols
- Appetite Suppression
Reduce appetite and support weight management goals
Safe default: 1mg · daily (investigational) · SubQ
- Libido / SexualPrimary
Enhance sexual desire and function
Safe default: 1.75mg · on demand (max 1/24h, 8/month) · SubQ
Simulate PT-141 (Bremelanotide)
Pinned.life runs a 1-compartment Bateman pharmacokinetic simulation against 38 peptides in real time. Build a stack, see serum-level curves, get warned about peak overlaps and drug-peptide interactions.